VistaGen

The Neuropsychiatric Pipeline: 10 Late-Stage Therapies to Watch
BioSpace
Mon, 08/14/23 - 11:23 am
depression
Biogen
SAGE Therapeutics
zuranolone
Intra-Cellular Therapies
lumateperone
Alto Neuroscience
ALTO-100
schizophrenia
Karuna Therapeutics
KarXT
Cerevel Therapeutics
emraclidine
Acadia Pharmaceuticals
pimavanserin
Axesome Therapeutics
AXS-05
Alzheimer's agitation
NRx
NRX-101
bipolar disorder
Biohaven
troriluzole
OCD
VistaGen
fasedienol
social anxiety
Vistagen back on track with social anxiety trials
Clinical Trials Arena
Fri, 08/11/23 - 10:01 am
VistaGen
social anxiety
fasedienol
RWE
clinical trials
Vistagen Pops 677% on Social Anxiety Spray Trial Success
Yahoo/Bloomberg
Mon, 08/7/23 - 11:02 pm
VistaGen
clinical trials
fasedienol
social anxiety
VistaGen shakes up Phase III social anxiety disorder program
Clinical Trials Arena
Fri, 03/31/23 - 10:34 am
VistaGen
clinical trials
social anxiety
fasedienol
VistaGen finds open-label success with social anxiety nasal spray, but PALISADE pivotal trial remains iced
Fierce Biotech
Wed, 03/22/23 - 09:21 pm
VistaGen
nasal spray
social anxiety
open-label
PH94B
Vistagen, jittery after seeing rivals fail, pauses plan to restart phase 3 anxiety trial pending FDA talks
Fierce Biotech
Wed, 02/8/23 - 10:27 am
VistaGen
FDA
clinical trials
anxiety
PH94B
Vistagen acquires Pherin Pharmaceuticals for 12.4M shares and 'nominal' cash
Endpoints
Thu, 12/22/22 - 10:49 am
VistaGen
Pherin Pharmaceuticals
M&A
Walls close in on VistaGen's PALISADE anxiety trial program in wake of phase 3 failure
Fierce Biotech
Sun, 08/14/22 - 10:37 pm
VistaGen
anxiety
clinical trials
social anxiety
VistaGen can’t puff out phase 3 success for social anxiety nasal spray
Fierce Biotech
Fri, 07/22/22 - 11:24 am
VistaGen
social anxiety
clinical trials
PH94B
VistaGen says regulators couldn’t sniff out abuse potential of its nasal spray for social anxiety
Fierce Biotech
Sun, 05/8/22 - 12:14 pm
VistaGen
social anxiety
PH94B
clinical trials
FDA
VistaGen fails phase 2 depression trial, sparking stock rout
Fierce Biotech
Thu, 11/14/19 - 10:36 am
VistaGen
AV-101
major depressive disorder
clinical trials
VistaGen’s AV-101 Snags Fast Track Designation, Other Drugmakers Move Ahead with Non-Opioid Pain Treatment Programs
BioSpace
Mon, 10/8/18 - 09:53 am
VistaGen
AV-101
FDA
fast track
neuropathic pain
BioWave
Virpax Pharmaceuticals
VistaGen raises $36M for stem cell tech
Fierce Biotech
Wed, 04/10/13 - 11:33 am
stem cells
VistaGen